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Abstract
Dosing is potentially the most important decision that must be made when building or refining
behavioral interventions. In this paper, we propose standardized terminology and reporting of
dosing information, which would inform intervention development, refinement for dissemination,
and systematic reviews of dose-response relationships. Dosing of interventions may be
characterized by duration, frequency, and amount. To illustrate the value of operationalizing these
three parameters to evaluate dose-response relationships, 31 published reports of behavioral
interventions to increase adherence to antiretroviral therapy (ART) were reviewed. The ART
literature was characterized by under-reporting of dosing parameters, heterogeneity in dosing
schedules, and heterogeneity in type of control group, which complicate analysis of dose-response
relationships in systematic review and determination of the optimal dose for intervention
dissemination. Improved reporting of the three dosing parameters and comparison of intended to
actual delivery can inform the identification of the most effective intervention doses and the
efficient implementation of efficacious interventions in clinical practice.
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Among the many decisions to be made when building or refining interventions is choosing
the intended dose. Dosing decisions have implications for budgeting, staffing, space
allocation, and participant enrollment and retention. Insufficient dosing of a new
intervention can lead to premature conclusions about the ineffectiveness of a general
intervention approach if a different (but untested) dose would have been effective. Dosing
decisions must also be made when translating effective interventions in clinical practice
because the complexity and resource intensity of many interventions require dose
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modifications to be feasible in many practice settings. In translating effective and, perhaps,
cost-effective interventions for broad dissemination, it would be ideal to provide guidance
on ways that the intervention dose could be modified while still retaining the intervention’s
effect size.
At present, there is little guidance to inform dosing decisions for new interventions or for
modifying the dose of existing interventions for translation into clinical practice. To inform
dosing decisions, there is a critical need for consensus in standardized terminology and
reporting of intervention dose. The goals of this paper are threefold: to propose the use of
standardized terminology for intervention dosing parameters, to describe the challenges in
comparing those parameters across interventions, and to highlight the intervention dosing
information that should be reported to facilitate examination of dose-response relationships
for intervention refinement and systematic reviews.
To illustrate the value of operationalizing dosing parameters, published reports of behavioral
interventions to increase adherence to antiretroviral therapy (ART) were reviewed. Through
this illustrative review, we identify critical issues in the reporting of intervention dosing
within and across studies that could be improved to support systematic intervention
development, refinement for dissemination, and systematic reviews of dosing elements that
are most predictive of patient outcomes. We conclude with recommendations that will
facilitate dosing decisions for developing new interventions, refining existing interventions,
and systematically reviewing dose-response relationships.
Operationalizing Behavioral Intervention Dose
Dose is defined as the “exact amount of a medicine or extent of some other treatment to be
given or taken at one time or at stated intervals.”[1] Yet, dose is variously operationalized.
Drawing from a concept analysis that was conducted to identify and define nurse dose,[2]
three dose parameters—duration, frequency, and amount—can be defined and
operationalized across various types of interventions. Duration is the amount of time over
which the intervention is intended to be administered (e.g., 12 weeks or 52 weeks).
Frequency is how often contact is intended to be made with participants per unit of time
(e.g., one contact per week or per month). Amount is the length of each contact between the
interventionist and participant (e.g., 5 minutes, 1 hour). Interactions between duration,
frequency, and amount represent another potentially meaningful aspect of dose. The
interaction between duration and frequency is the total number of contacts made. The three-
way interaction is the total cumulative number of minutes of intervention delivered.
Given these definitions, one could conduct structured comparative effectiveness trials to
evaluate the impact of different dosing schedules. For example, one could hold the intended
amount fixed (1-hour sessions) and compare whether a more compressed schedule with
greater frequency (one contact per week) and shorter duration (12 weeks) was more
effective than a less compressed schedule with lesser frequency (one contact per month) and
a longer duration (12 months). Alternatively, one could hold the intended duration fixed (12
weeks) and compare whether less frequent contact (one contact every other week) of greater
amount (2 hours) was more effective than more frequent contact (one contact per week) of
lesser amount (1 hour). In these examples, the total time of patient-interventionist interaction
was held constant at 12 hours. One could also compare an intervention requiring 12 hours of
patient-interventionist interaction using a variable frequency, in which participants receive
more frequent contact initially and then less frequent contact over time.
Given that comparative effectiveness trials manipulating intervention dosing parameters are
relatively infrequent, a potentially more accessible way to understand which dosing
parameters and which levels of each parameter generate more effective interventions is
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through systematic review. Examinations of dose-response relationships in systematic
reviews typically involve only one aspect of dose and do not jointly consider duration,
frequency, and amount. For example, in a meta-analysis of behavioral interventions to
increase adherence to highly active ART,[3] a dichotomous covariate representing 5 or more
sessions versus fewer than 5 sessions did not account for a significant proportion of variance
in the effect size. More variance may have been explained if other dosing parameters had
been examined. Ideally, people designing, refining, and disseminating interventions would
like to be informed about all parameters of dosing as these parameters may work in concert,
may interact with one another (the whole is greater than [or less than] the sum of its parts),
or some parameters may be more predictive of patient outcomes than other parameters.
Illustrative Data Set
To experience firsthand and illustrate the challenges in comparing interventions along these
three dosing parameters, we systematically reviewed 31 reports of randomized controlled
trials that evaluated interventions to improve patient adherence to ART. The data set was
assembled as part of a larger study to develop and evaluate methods for conducting mixed-
methods research syntheses [4] and was based on a search of six databases (Academic
Search Premier, CINHAL, PubMed, PsychINFO, Sociological Abstracts, and The Cochrane
Library). Inclusion criteria for this search included: conducted in the US, published between
2000 and 2009, medication adherence as an outcome, and sufficient information to calculate
the effect size. For this paper, we excluded studies that involved minimal human contact
(e.g., provision of educational materials or pill boxes) or in which the only difference
between intervention and control groups was something other than human contact (e.g.,
reminders from a pager). For the purposes of this paper, we chose to assess only on the dose
of the human contact portion of the intervention even if human contact was supplemented
with devices or intervention materials such as videos or written materials because dosing
parameters for these intervention components would be difficult to determine.
To use dosing data in a meta-regression to examine dose-response relationships, the data
must be reduced to a common denominator. To illustrate, duration was calculated in weeks,
frequency in times per week, and amount in minutes (Table 1). Values were averaged across
components in the case of multi-component interventions (e.g., comprising in-person group
sessions and individual telephone interviews). In a meta-regression, the dependent would be
the effect size representing the difference in outcomes between intervention and control
groups; the independent variables would be between-group differences in the dosing
parameters, which could be calculated from the information provided in Table 1.
Challenge 1: Under-Reporting of Dosing Parameters
One challenge to comparing interventions along dosing parameters is under-reporting of
dosing information. As shown in Table 1, there was inconsistency in the completeness of
reporting across the three parameters. Intended duration was always reported. Intended
frequency was reported less often; commonly, authors reported the total number of contacts
without reporting the interval at which the contacts occurred. Therefore, frequency was
calculated by dividing the total number of contacts by the duration.
Data were least likely to be reported for amount (missing in 12 out of 31 reports). Moreover,
amount tended to be reported as delivered rather than as intended, often as a mean or median
and sometimes accompanied by a standard deviation or range. Although reporting of
intended delivery is necessary to evaluate the efficacy or effectiveness of an intervention on
the basis of intent-to-treat principles, comparison of actual to intended delivery enables the
evaluation of mediators and provides information on whether some intervention doses are
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likely to be infeasible because the intended delivery is rarely provided. Significant
differences between intended and actual delivery may indicate that interventionists have
practical difficulty with fidelity to the protocol and/or that patients have difficulty adhering
to the prescribed intervention. In the reports that included data on actual delivery, the
authors indicated that actual delivery was somewhat less than intended. Such differences
may suggest that a more modest intervention dose may reduce the risk of challenges with
fidelity to the intended intervention, patient attrition due to drop out, and excess intervention
costs.
Challenge 2: Heterogeneity in Dosing Schedules
Another challenge to comparing interventions along dosing parameters is that dosing
schedules may vary between studies and between participants in the same study. Dosing
schedules may be fixed (i.e., the schedule is constant throughout the study duration) or
variable (i.e., the dose changes during the study) and may be tailored (i.e., delivered
according to participant needs or progress) or untailored (i.e., applied similarly to all
participants). In Ma (2008), the directly observed therapy intervention was delivered 5 times
per week for the first 12 weeks, 4 times per week for the next 3 weeks, 3 times per week for
the next 3 weeks, twice per week for the next 3 weeks, and once per week for the final 3
weeks to all participants (variable, non-tailored). In Rathbun (2005), participants had in-
person visits at baseline and then 2 weeks later, with an intervening telephone call and then
additional follow-up for participants who needed it (variable, tailored). Because mean values
for frequency and amount obscure these subtle differences in dosing schedules, additional
variables may be created representing fixed versus variable and tailored versus untailored
dosing schedules (last two columns of Table 1).
Challenge 3: Heterogeneity in Types of Control Groups
Heterogeneity in the type of control group also poses a challenge for comparing intervention
dosing parameters. In our data set of ART adherence interventions, there were three types of
control groups: usual care, enhanced usual care, and attention control. For usual care control
groups, ascertaining between-group differences in dosing parameters may be difficult
because authors rarely report on the resources used by usual care participants during the
study period. When synthesizing findings, one could assume that usual care participants
receive no additional care, as we did here, so that between-group differences in dosing
parameters represent the amount incurred by the intervention group.
In the case of an enhanced usual care group (i.e., participants receive some level of
intervention but not a comparison intervention), the duration, frequency, and amount of care
received by the control group is assumed to be greater than zero. As with usual care groups,
however, assigning values for each parameter may be challenging given the lack of detail on
the intervention provided to enhance usual care.
Finally, in studies that include an attention control group, duration, frequency, and amount
of contact may or may not be equal to those of the intervention group (i.e., the difference
between groups is zero). If they are assumed to be equal, then the treatment and control
groups differ only on intervention content. However, the extent to which equivalence was
achieved is often difficult to evaluate given the absence of dosing data on the control group.
Discussion
Dose is often examined in systematic reviews and reports of primary research studies
directed toward identifying why some interventions are efficacious or effective and others
are not. Yet, dose may be misconstrued as a unidimensional parameter (e.g., number of
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intervention contacts) while other aspects of intervention dose are ignored. We propose
standardized terminology for intervention dosing—duration, frequency, and amount—that
should be reported consistently to facilitate the use of dosing data in systematic
examinations of dose-response relationships for the purpose of intervention development
and refinement for dissemination.
One aspect of dosing that has been promoted but that we did not operationalize is purity,
which has been defined as the “concentration of active elements of a treatment” (p. 312).[2]
Purity is an aspect of dosing that differentiates an intervention group from an attention
control group matched for duration, frequency, and amount. In a concept analysis conducted
to yield aspects of nurse dose, purity was operationalized as the nurse’s knowledge, which
was indicated by education, experience, and skill mix.[2] The authors suggested that purity
of behavior therapy is “information or instructions given to address the presenting clinical
problem.” Deriving values for purity of behavioral interventions may be challenging
because the active ingredient may relate not only to interventionist knowledge and
experience, as proposed for nurse dose, but also to intervention content or approach (e.g.,
education, training, social support).[5] Future work is needed to operationalize this concept
in the context of behavioral interventions.
Although the approach to dosing outlined in this paper was illustrated with a review of
behavioral interventions for ART adherence, they are not limited to such interventions.
Previous literature has underscored a general tendency to under-report information on
interventions across different therapeutic areas.[6] Lack of reporting of dosing information
also challenges efforts to synthesize literature on the relationship between medications and
patient outcomes. For example, in a Cochrane review comparing paracetemol to
nonsteroidal anti-inflammatory agents for rheumatoid arthritis, it was noted that the reports
did not include justification for the doses examined and therefore it was unclear whether
equipotent doses were examined.[7]
Conclusions
On the basis of the challenges we identified, we make several specific recommendations that
will facilitate the examination of dosing in systematic reviews of the literature, which is
critical to assessing the comparative effectiveness of different intervention options and for
translating existing interventions into clinical practice. To build the evidence base on dosing,
investigators, when planning studies, should develop a plan to assess intervention fidelity
that includes an assessment of how many intervention contacts are actually made and how
long each contact lasts. This information will allow comparison of values for actual and
intended duration, frequency and amount of intervention delivered, which will inform
whether deviation in fidelity to the intervention protocol is a source of variation in outcomes
within the treatment arm and across similar interventions from different studies.
Investigators should also standardize training across interventionists to improve the
likelihood of an equal level of skill, which may enhance the correspondence between
intended and actual delivery. Finally, sufficient detail on intended and actual duration,
frequency, and amount should be included in reports of intervention studies so that the
relationship between dosing and patient outcomes can be investigated more fully in
systematic reviews. To complement these efforts, intervention banks can be created whereby
intervention detail, including manuals, videos, written materials can be stored and accessed
by individuals designing studies or conducting systematic reviews.[8]
We hope that, by conceptualizing and operationalizing intervention dose, investigators will
be poised to collect this information in their trials and include it in published reports. The
use of standardized dosing terminology and consistent detailed reporting on intervention
dose along these parameters will allow investigators and reviewers alike better to design
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new interventions, to translate efficacious interventions in clinical practice, and to
systematically review dose-response relationships.
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